Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients
Retrieved on:
Tuesday, November 30, 2021
Koto, HLHS, National Center for Health Research, Trial of the century, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ageing, Safety, Mental health, Cell, Disorder, Hypoplastic left heart syndrome, Frailty, Forward-looking statement, Company, Population, Achievement, Microsoft, Prevalence, SEC, Blood, Systematic review, Food, Longevity, Intussusception (medical disorder), Goal, Metabolic syndrome, Cytokine, Journal of Epidemiology, GLOBE, Adult, Meta-analysis, Terminology, Patent, Bone marrow, PMDA, Intention, Walking, NASDAQ, Medicines and Healthcare products Regulatory Agency, Pharmaceutical industry, Medicine
The overall prevalence of frailty amongst this demographic is estimated to be 7.9% [1]
Key Points:
- The overall prevalence of frailty amongst this demographic is estimated to be 7.9% [1]
Lomecel-B has been evaluated in Phase 1 & 2 aging frailty clinical studies in the U.S. - A Phase 2 clinical trial is currently underway in babies with HLHS.
- The Japanese Phase 2 study is a randomized, double-blind, placebo-controlled design approved by Japans Pharmaceuticals and Medical Devices Agency (PMDA).
- Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimers disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).